Key facts
- Xeptiva Therapeutics’s last known valuation is $10.0M (Jul 2024).
- It has raised $4.3M; the latest was Early Stage VC ($1.8M) in Sep 2025.
- Notable investors include Fen Ventures, NDLatam, Seedstars International Ventures, Sergio Fogel Kaplan, Uruguay Biotech Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Xeptiva Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Xeptiva Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xeptiva Therapeutics
Developer of an immunotherapy platform designed to address chronic inflammatory conditions in companion animals. The company's platform offers active therapeutic vaccines for disorders such as osteoarthritis, atopic dermatitis, chronic pain, and obesity, enabling pet owners and veterinary professionals, to improve health span and lifespan through affordable and effective immune-based treatments.
- Sector
- Business Products and Services (B2B)
- HQ
- Montevideo, Uruguay
- Founded
- 2021
- Employees
- 11
- Website
- xeptiva.com/
- Ownership
- Privately Held (backing)
Xeptiva Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xeptiva Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xeptiva Therapeutics in its N-PORT filings yet. We sweep new filings monthly.